{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:44:53Z","timestamp":1793677493562,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck & Co., Inc., Kenilworth, NJ"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To estimate the cost of six different techniques used to treat Genital Warts and the annual average cost of treating a typical GW patient in Peru. To estimate the annual economic burden diagnosing and treating GW in the Peruvian public healthcare system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed a prevalence-based, cost-of-illness study from the provider\u2019s perspective, the healthcare facilities under the purview of Peruvian Ministry of Health. We used an activity-based costing approach. We conducted primary data collection in three regions in Peru and supplemented it with governmental data. Uncertainty of the costing estimates was assessed via Monte Carlo simulations. We estimated the average cost and associated confidence intervals for six treatment options \u2013 three topical and three surgical \u2013 and the overall cost per patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average treatment cost per patient was 59.9USD (95\u00a0%CI 45.5, 77.6). Given a population of 18.4\u00a0million adults between 18 and 60 years of age and a GW prevalence of 2.28\u2009%, the annual cost of treating GW was 25.1\u00a0million USD (uncertainty interval 16.9, 36.6).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides the first quantification of the economic burden of treating genital warts in Peru and one of the few in Latin America. The costing data did not include other healthcare providers or out-of-pocket expenditures, and hence we present a conservative estimate of the COI of GW in Peru. Our findings bring attention to the financial burden of treating GW, a vaccine-preventable disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-07120-w","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T14:52:04Z","timestamp":1634223124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Annual costs of treating genital warts in the Public Healthcare Sector in Peru"],"prefix":"10.1186","volume":"21","author":[{"given":"Enrique M","family":"Saldarriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar P.","family":"C\u00e1rcamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Babigumira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"7120_CR1","doi-asserted-by":"crossref","unstructured":"Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013 Jan 25;13(1):39.","DOI":"10.1186\/1471-2334-13-39"},{"key":"7120_CR2","doi-asserted-by":"crossref","unstructured":"Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009 Mar 15;199(6):805\u201314.","DOI":"10.1086\/597071"},{"key":"7120_CR3","unstructured":"McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in Adults Aged 18\u201369: United States, 2011\u20132014. NCHS Data Brief. 2017 Apr;(280):1\u20138."},{"key":"7120_CR4","doi-asserted-by":"crossref","unstructured":"Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MCB, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013 Mar;40(3):187\u201393.","DOI":"10.1097\/OLQ.0b013e318286bb53"},{"key":"7120_CR5","unstructured":"Lynde C, Vender R, Bourcier M, Bhatia N. Clinical features of external genital warts. J Cutan Med Surg. 2013 Dec;17 Suppl 2:S55-60."},{"key":"7120_CR6","doi-asserted-by":"crossref","unstructured":"Garc\u00eda PJ, Carcamo CP, Valderrama M, La Rosa S, James C, Guti\u00e9rrez R, et al. Burden of genital warts in Peru: an observational study. Int J STD AIDS. 2019 Mar;30(3):264\u201374.","DOI":"10.1177\/0956462418796088"},{"issue":"1","key":"7120_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11255-005-4986-3","volume":"39","author":"M Kilciler","year":"2007","unstructured":"Kilciler M, Bedir S, Erdemir F, Coban H, Erten K, Ors O, et al. Condylomata acuminata of external urethral meatus causing infravesical obstruction. Int Urol Nephrol. 2007;39(1):107\u20139.","journal-title":"Int Urol Nephrol"},{"key":"7120_CR8","doi-asserted-by":"crossref","unstructured":"Chae JY, Bae JH, Yoon CY, Park HS, Moon DG, Lee JG, et al. Female Urethral Condyloma Causing Bladder Outlet Obstruction. Int Neurourol J. 2014 Mar;18(1):42\u20134.","DOI":"10.5213\/inj.2014.18.1.42"},{"key":"7120_CR9","unstructured":"Workowski KA, Bolan G. Sexually Transmitted Diseases Treatment Guidelines, 2015 [Internet]. Centers for Disease Control and Prevention - CDC; 2015. Report No.: 64(RR2); 1\u2013137. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6403a1.htm"},{"key":"7120_CR10","doi-asserted-by":"crossref","unstructured":"Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Oct;87(6):458\u201363.","DOI":"10.1136\/sextrans-2011-050073"},{"issue":"2","key":"7120_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0950268817002813","volume":"146","author":"YJ Park","year":"2018","unstructured":"Park YJ, Kim JM, Lee BR, Kim TH, Lee EG. Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015. Epidemiol Infect. 2018;146(2):177\u201386.","journal-title":"Epidemiol Infect"},{"key":"7120_CR12","doi-asserted-by":"crossref","unstructured":"Coles V a. H, Chapman R, Lanitis T, Carroll SM. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland. Int J STD AIDS. 2016 Jan;27(1):51\u20137.","DOI":"10.1177\/0956462415573121"},{"key":"7120_CR13","doi-asserted-by":"crossref","unstructured":"Domenech-Vi\u00f1olas M, Le\u00f3n-Maldonado L, Ram\u00edrez-Palacios P, Flores YN, Granados-Garc\u00eda V, Brown B, et al. Incidence, psychosocial burden, and economic impact of genital warts in Mexico. Salud Publica Mex. 2018 Nov;60(6):624\u201332.","DOI":"10.21149\/10008"},{"key":"7120_CR14","doi-asserted-by":"crossref","unstructured":"Roldos M, Bustamante V. Consensus of Clinical Practices And Associated Costs To Diagnose And Treat Genital Warts Caused By Human Papilloma Virus (Hpv) In Ecuador: Results From A Panel Of Experts. Value Health. 2015 Nov 1;18:A833.","DOI":"10.1016\/j.jval.2015.09.331"},{"key":"7120_CR15","doi-asserted-by":"crossref","unstructured":"Reyes-Lopez A, P\u00e9rez Bolde-Villarreal C, Pastor-Martinez V. Uso de recursos y costos asociados al diagn\u00f3stico y tratamiento de las verrugas genitales en instituciones p\u00fablicas de salud en M\u00e9xico. Rev Mex Urol. 2015 Mar 1;75:72\u201381.","DOI":"10.1016\/j.uromx.2015.01.004"},{"issue":"Suppl 2","key":"7120_CR16","first-page":"s243-254","volume":"53","author":"JE Alcalde-Rabanal","year":"2011","unstructured":"Alcalde-Rabanal JE, Lazo-Gonz\u00e1lez O, Nigenda G. [The health system of Peru]. Salud Publica Mex. 2011;53 Suppl 2:s243-254.","journal-title":"Salud Publica Mex"},{"key":"7120_CR17","unstructured":"Durand-Carrion D. [Population with any kind of health insurance] [Internet]. Lima: Instituto Nacional de Estad\u00edstica e Inform\u00e1tica - INEI; 2018 Nov. Available from: https:\/\/www.inei.gob.pe\/media\/MenuRecursivo\/publicaciones_digitales\/Est\/Lib1587\/libro01.pdf"},{"key":"7120_CR18","doi-asserted-by":"crossref","unstructured":"Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jer\u00f3nimo J, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008 Aug 19;26 Suppl 11:L37-48.","DOI":"10.1016\/j.vaccine.2008.06.013"},{"key":"7120_CR19","unstructured":"MINSA. Resoluci\u00f3n Ministerial 651-2016-MINSA. Ministerio de Salud - MINSA; 2016 Agosto."},{"key":"7120_CR20","doi-asserted-by":"crossref","unstructured":"Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context\u2014A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value Health. 2018 Feb;21(2):124\u201330.","DOI":"10.1016\/j.jval.2017.12.006"},{"key":"7120_CR21","doi-asserted-by":"crossref","unstructured":"Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-Illness Studies. PharmacoEconomics. 2006 Sep 1;24(9):869\u201390.","DOI":"10.2165\/00019053-200624090-00005"},{"key":"7120_CR22","doi-asserted-by":"crossref","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014 Dec;20(4):327\u201337.","DOI":"10.3350\/cmh.2014.20.4.327"},{"key":"7120_CR23","unstructured":"DGSP, DAIS. [National Guidelines for integral care of Sexual and reproductive health] [Internet]. Lima, Peru: Ministry of Health; 2004. Available from: http:\/\/bvs.minsa.gob.pe\/local\/dgsp\/63_guiasnac.pdf"},{"key":"7120_CR24","unstructured":"Lau F. Chapter 14 Methods for eHealth Economic Evaluation Studies [Internet]. Handbook of eHealth Evaluation: An Evidence-based Approach [Internet]. University of Victoria; 2017 [cited 2021 Jun 28]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK481607\/"},{"key":"7120_CR25","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes [Internet]. Oxford, UNITED KINGDOM: Oxford University Press; 2015 [cited 2021 May 31]. Available from: http:\/\/ebookcentral.proquest.com\/lib\/washington\/detail.action?docID=4605509"},{"issue":"1","key":"7120_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","volume":"8","author":"A Briggs","year":"2005","unstructured":"Briggs A. Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty. Value Health. 2005;8(1):1\u20132.","journal-title":"Value Health"},{"key":"7120_CR27","doi-asserted-by":"crossref","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Mak Int J Soc Med Decis Mak. 2012 Oct;32(5):722\u201332.","DOI":"10.1177\/0272989X12458348"},{"key":"7120_CR28","unstructured":"INEI. [Total population at June 30 of every year, by sex and age groups] [Internet]. Instituto Nacional de estadistica e Informatica - INEI; ND. Available from: https:\/\/www.inei.gob.pe\/estadisticas\/indice-tematico\/poblacion-y-vivienda\/"},{"key":"7120_CR29","unstructured":"Rosen AB, Aizcorbe A, Highfill T, Chernew ME, Liebman E, Ghosh K, et al. Attribution of Health Care Costs to Diseases: Does the Method Matter? In: Measuring and Modeling Health Care Costs [Internet]. University of Chicago Press; 2016 [cited 2021 Aug 2]. p.\u00a0173\u2013210. Available from: https:\/\/www.nber.org\/books-and-chapters\/measuring-and-modeling-health-care-costs\/attribution-health-care-costs-diseases-does-method-matter"},{"key":"7120_CR30","unstructured":"Pavone MP, S\u00e1nchez EJ. Determinants of out-of-pocket spending on health among the poor population served by public health services in Peru, 2010\u20132014. Rev Panam Salud P\u00fablica. 2018 Oct 18;42:e20."},{"key":"7120_CR31","unstructured":"Peruvian Ministry of Economic and Finance. [Friendly Search (Monthly). Public Expenditure Execution Search] [Internet]. Economic Transparency. [cited 2020 Jan 15]. Available from: http:\/\/apps5.mineco.gob.pe\/transparencia\/mensual\/"},{"key":"7120_CR32","unstructured":"The World Bank. PPP conversion factor [Internet]. [cited 2021 Apr 5]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP"},{"key":"7120_CR33","doi-asserted-by":"crossref","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10;356(19):1928\u201343.","DOI":"10.1056\/NEJMoa061760"},{"key":"7120_CR34","doi-asserted-by":"crossref","unstructured":"FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915\u201327.","DOI":"10.1056\/NEJMoa061741"},{"key":"7120_CR35","unstructured":"Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630\u20132."},{"key":"7120_CR36","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2007 Mar 23;56(RR-2):1\u201324.","DOI":"10.1037\/e601292007-001"},{"key":"7120_CR37","doi-asserted-by":"crossref","unstructured":"Meites E. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2019 Oct 25];68. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/68\/wr\/mm6832a3.htm","DOI":"10.15585\/mmwr.mm6832a3"},{"key":"7120_CR38","doi-asserted-by":"crossref","unstructured":"Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, et al. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction\u2014National Health and Nutrition Examination Survey, United States, 2003\u20132014. J Infect Dis. 2017 Sep 1;216(5):594\u2013603.","DOI":"10.1093\/infdis\/jix244"},{"key":"7120_CR39","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016 Mar 1;137(3):e20151968.","DOI":"10.1542\/peds.2015-1968"},{"key":"7120_CR40","doi-asserted-by":"crossref","unstructured":"Garland SM, Skinner SR, Brotherton JML. Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Prev Med. 2011 Oct 1;53:S29\u201335.","DOI":"10.1016\/j.ypmed.2011.08.015"},{"key":"7120_CR41","doi-asserted-by":"crossref","unstructured":"Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013 Apr 18;346:f2032.","DOI":"10.1136\/bmj.f2032"},{"key":"7120_CR42","doi-asserted-by":"crossref","unstructured":"Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance [Internet]. 2018 Oct 11 [cited 2019 Oct 25];23(41). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6194907\/","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"key":"7120_CR43","doi-asserted-by":"crossref","unstructured":"Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJLM, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015 May 12;350:h2016.","DOI":"10.1136\/bmj.h2016"},{"key":"7120_CR44","doi-asserted-by":"crossref","unstructured":"Elfstr\u00f6m KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016 Jan 15;213(2):199\u2013205.","DOI":"10.1093\/infdis\/jiv368"},{"key":"7120_CR45","doi-asserted-by":"crossref","unstructured":"Hintze JM, O\u2019Neill JP. Strengthening the case for gender-neutral and the nonavalent HPV vaccine. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2018 Apr;275(4):857\u201365.","DOI":"10.1007\/s00405-018-4866-y"},{"key":"7120_CR46","doi-asserted-by":"crossref","unstructured":"Ortiz AP, Ortiz-Ortiz KJ, R\u00edos M, Laborde J, Kulkarni A, Pillsbury M, et al. Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico. PLoS ONE. 2017 Nov 30;12(11):e0184540.","DOI":"10.1371\/journal.pone.0184540"},{"key":"7120_CR47","doi-asserted-by":"crossref","unstructured":"Bardach AE, Garay OU, Calder\u00f3n M, Pich\u00f3n-Rivi\u00e9re A, Augustovski F, Mart\u00ed SG, et al. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017 Feb 2;17:152.","DOI":"10.1186\/s12889-017-4064-7"},{"key":"7120_CR48","doi-asserted-by":"crossref","unstructured":"Frick KD. Micro-Costing Quantity Data Collection Methods. Med Care. 2009 Jul;47(7 Suppl 1):S76\u201381.","DOI":"10.1097\/MLR.0b013e31819bc064"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-07120-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T15:04:35Z","timestamp":1634223875000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-07120-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7120"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-07120-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and instruments were reviewed and approved by the IRB of the Universidad Peruana Cayetano Heredia (# 65616). All protocols are carried out in accordance with relevant guidelines and regulations. Participants were aware of the study and understood the benefits and risks involved. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Merck & Co., Inc., produces Gardasil 4-valent HPV vaccine however, the funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors have no competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1092"}}